Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base

•Administration of adjuvant chemotherapy results is better survival for OYSTs.•Age and disease stage are independently associated with mortality.•Lymphadenectomy and omentectomy may be omitted when staging OYSTs. To evaluate the clinico-pathological characteristics, management and prognosis of women...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2017-11, Vol.147 (2), p.296-301
Main Authors: Nasioudis, Dimitrios, Chapman-Davis, Eloise, Frey, Melissa K., Caputo, Thomas A., Holcomb, Kevin
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Chemotherapy
Child
Child, Preschool
Databases, Factual
Endodermal sinus tumor
Endodermal Sinus Tumor - diagnosis
Endodermal Sinus Tumor - mortality
Endodermal Sinus Tumor - therapy
Female
Humans
Infant
Malignant ovarian germ cell tumor
Middle Aged
Neoplasm Staging
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - mortality
Ovarian Neoplasms - therapy
Ovary
Prognosis
United States - epidemiology
Yolk sac tumor
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Administration of adjuvant chemotherapy results is better survival for OYSTs.•Age and disease stage are independently associated with mortality.•Lymphadenectomy and omentectomy may be omitted when staging OYSTs. To evaluate the clinico-pathological characteristics, management and prognosis of women diagnosed with ovarian yolk sac tumors (OYSTs). The U.S National Cancer Data Base was queried for women diagnosed with OYST between 2004 and 2014. Overall survival (OS) was calculated following generation of Kaplan-Meir curves. Univariate analysis was performed with the log-rank test. A Cox model was constructed to determine independent predictors of mortality. A total of 561 women were identified with a median age of 23years. The majority (58.5%) had early stage (I–II), while 29.6% and 11.9% had stage III and IV disease respectively. Five-year OS for women with stage I, II, III and IV disease were 94.8%, 97.1%, 70.9% and 51.6% respectively, p
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2017.08.013